BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 11209975)

  • 1. Platelet activation by ADP: the role of ADP antagonists.
    Gachet C
    Ann Med; 2000 Dec; 32 Suppl 1():15-20. PubMed ID: 11209975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADP receptors of platelets and their inhibition.
    Gachet C
    Thromb Haemost; 2001 Jul; 86(1):222-32. PubMed ID: 11487010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective.
    Packham MA; Mustard JF
    Semin Thromb Hemost; 2005 Apr; 31(2):129-38. PubMed ID: 15852216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The P2 receptors in platelet function.
    Hechler B; Cattaneo M; Gachet C
    Semin Thromb Hemost; 2005 Apr; 31(2):150-61. PubMed ID: 15852218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.
    Gachet C
    Pharmacol Ther; 2005 Nov; 108(2):180-92. PubMed ID: 15955565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
    Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
    Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The platelet P2 receptors in thrombosis.
    Gachet C; Hechler B
    Semin Thromb Hemost; 2005 Apr; 31(2):162-7. PubMed ID: 15852219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors.
    Baurand A; Eckly A; Bari N; Léon C; Hechler B; Cazenave JP; Gachet C
    Thromb Haemost; 2000 Sep; 84(3):484-91. PubMed ID: 11019976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation.
    Léon C; Vial C; Gachet C; Ohlmann P; Hechler B; Cazenave JP; Lecchi A; Cattaneo M
    Thromb Haemost; 1999 May; 81(5):775-81. PubMed ID: 10365753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice.
    Léon C; Hechler B; Freund M; Eckly A; Vial C; Ohlmann P; Dierich A; LeMeur M; Cazenave JP; Gachet C
    J Clin Invest; 1999 Dec; 104(12):1731-7. PubMed ID: 10606627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADP receptors and clinical bleeding disorders.
    Cattaneo M; Gachet C
    Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2281-5. PubMed ID: 10521355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADP-induced platelet activation.
    Puri RN; Colman RW
    Crit Rev Biochem Mol Biol; 1997; 32(6):437-502. PubMed ID: 9444477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P2Y12, a new platelet ADP receptor, target of clopidogrel.
    Herbert JM; Savi P
    Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel.
    Hechler B; Eckly A; Ohlmann P; Cazenave JP; Gachet C
    Br J Haematol; 1998 Dec; 103(3):858-66. PubMed ID: 9858246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification, characterization, and inhibition of the platelet ADP receptors.
    Gachet C
    Int J Hematol; 2001 Dec; 74(4):375-81. PubMed ID: 11794691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine diphosphate receptors on blood platelets: potential new targets for antiplatelet therapy.
    Rozalski M; Nocun M; Watala C
    Acta Biochim Pol; 2005; 52(2):411-5. PubMed ID: 15912207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.
    Fagura MS; Dainty IA; McKay GD; Kirk IP; Humphries RG; Robertson MJ; Dougall IG; Leff P
    Br J Pharmacol; 1998 May; 124(1):157-64. PubMed ID: 9630355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice.
    Fabre JE; Nguyen M; Latour A; Keifer JA; Audoly LP; Coffman TM; Koller BH
    Nat Med; 1999 Oct; 5(10):1199-202. PubMed ID: 10502826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The platelet P2 receptors in arterial thrombosis.
    Gachet C; Léon C; Hechler B
    Blood Cells Mol Dis; 2006; 36(2):223-7. PubMed ID: 16466948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of P2Y1 purinoceptor in ADP-induced platelet activation.
    Savi P; Beauverger P; Labouret C; Delfaud M; Salel V; Kaghad M; Herbert JM
    FEBS Lett; 1998 Feb; 422(3):291-5. PubMed ID: 9498802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.